NYSE$LLY
Eli Lilly & Co · Q1 2026 earnings
Q1 2026 earnings · · Before market open · Investor relations
Briefing
Eli Lilly reported Q1 2026 revenue of $19.8B and net income of $7.4B, with diluted EPS of $8.26.
Lilly generated Q1 2026 revenue of $19.8 billion (+56% YoY), including net product revenue of $18.5 billion driven by Mounjaro and Zepbound. Net income was $7.4 billion, or $8.26 diluted EPS, versus $2.8 billion and $3.06. Gross margin expanded on GLP-1 scale while R&D and SG&A rose with pipeline investment.
- Total revenue $19.8B (+56% YoY); net product revenue $18.5B.
- Net income $7.4B; diluted EPS $8.26.
- Mounjaro and Zepbound represented 65% of total revenue.
- U.S. government drug-pricing agreements finalized in Q1.
- Higher R&D on obesity and Alzheimer's programs.
Headline financials
Revenue & EPS history
Eli Lilly · Revenue · Quarterly
$19.8B
Revenue by segment
Eli Lilly · $2.45B total across 2 segments · Q3 2023
- Mounjaro$1.41B+652.4%57.5%
- Verzenio$1.04B+68.4%42.5%
Forward guidance
The 10-Q discusses LLY's operating environment, capital priorities, and risks without issuing formal quarterly EPS guidance.
Tailwinds
- Management provides segment and liquidity detail in MD&A.
- Filing supports transparency on year-over-year trends.
Headwinds
- Macro, competitive, or regulatory risks noted in risk factors.
- No numeric full-year EPS bridge in the quarterly filing.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q1 2026
+0.1%
Avg return
Earnings day
+0.8%
Avg return
5 days after
+3.1%
Avg return
30 days after
43%
29 / 67 earnings
Positive
+15.9%
Q2 2023
Best reaction
-14.1%
Q2 2025
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -0.1% | +16.2% | +29.9% | |
| Q4 2025 | +10.3% | +4.1% | -1.3% | |
| Q3 2025 | +3.2% | +11.5% | +32.2% | |
| Q2 2025 | -14.1% | -14.3% | -2.6% | |
| Q1 2025 | -11.7% | -13.8% | -17.9% | |
| Q4 2024 | +3.3% | +2.7% | +3.3% | |
| Q3 2024 | -8.2% | -10.8% | -12.0% | |
| Q2 2024 | +15.5% | +17.6% | +16.9% | |
| Q1 2024 | +5.4% | -0.3% | +10.6% | |
| Q4 2023 | +2.7% | +4.8% | +10.5% | |
| Q3 2023 | +2.4% | +8.2% | +5.3% | |
| Q2 2023 | +15.9% | +16.3% | +26.2% | |
| Q1 2023 | +5.2% | +7.4% | +13.2% | |
| Q4 2022 | -1.0% | -0.8% | -7.0% | |
| Q3 2022 | -2.0% | -1.3% | +2.3% | |
| Q2 2022 | -4.0% | -3.4% | -4.0% | |
| Q1 2022 | +2.5% | +1.0% | +13.5% | |
| Q4 2021 | -3.4% | -4.4% | +4.8% | |
| Q3 2021 | +2.1% | +4.0% | +6.9% | |
| Q2 2021 | +6.4% | +6.8% | +5.3% | |
| Q1 2021 | -3.6% | -2.4% | +6.4% | |
| Q4 2020 | -3.3% | -6.3% | -2.5% | |
| Q3 2020 | -7.3% | -7.9% | +2.2% | |
| Q2 2020 | -7.1% | -4.3% | -8.9% | |
| Q1 2020 | +4.0% | +0.4% | -3.5% | |
| Q4 2019 | -0.2% | +2.5% | -9.9% | |
| Q3 2019 | -1.8% | +2.9% | +5.8% | |
| Q2 2019 | +0.2% | +3.4% | +3.2% | |
| Q1 2019 | -1.2% | -2.2% | -3.1% | |
| Q4 2018 | -2.4% | -2.0% | +5.2% | |
| Q3 2018 | -0.4% | +1.9% | +5.2% | |
| Q2 2018 | +8.5% | +8.7% | +17.9% | |
| Q1 2018 | +1.2% | +3.2% | +3.1% | |
| Q4 2017 | -4.3% | -10.0% | -10.3% | |
| Q3 2017 | -2.7% | -3.8% | -4.0% | |
| Q2 2017 | -3.4% | -1.9% | -6.9% | |
| Q1 2017 | -2.9% | -1.6% | -6.1% | |
| Q4 2016 | +3.9% | +3.4% | +11.0% | |
| Q3 2016 | -1.0% | -3.9% | -12.3% | |
| Q2 2016 | +1.7% | +1.1% | -4.8% | |
| Q1 2016 | -1.8% | — | — | |
| Q4 2015 | -3.3% | — | — | |
| Q3 2015 | +1.7% | — | — | |
| Q2 2015 | -1.9% | — | — | |
| Q1 2015 | -1.0% | — | — | |
| Q4 2014 | -0.6% | — | — | |
| Q3 2014 | +2.1% | — | — | |
| Q2 2014 | -0.7% | — | — | |
| Q1 2014 | -1.8% | — | — | |
| Q4 2013 | +0.2% | — | — | |
| Q3 2013 | +0.8% | — | — | |
| Q2 2013 | +3.1% | — | — | |
| Q1 2013 | -3.3% | — | — | |
| Q4 2012 | +2.9% | — | — | |
| Q3 2012 | -1.6% | — | — | |
| Q2 2012 | +3.9% | — | — | |
| Q1 2012 | +2.3% | — | — | |
| Q4 2011 | +1.0% | — | — | |
| Q3 2011 | -1.9% | — | — | |
| Q2 2011 | -0.1% | — | — | |
| Q1 2011 | -0.1% | — | — | |
| Q4 2010 | -1.6% | — | — | |
| Q3 2010 | -0.3% | — | — | |
| Q2 2010 | +2.5% | — | — | |
| Q1 2010 | +0.4% | — | — | |
| Q4 2009 | -0.8% | — | — | |
| Q4 2008 | -0.3% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro